



BE SWASTH HEALTHCARE LIMITED

CIN: L93000DL1985PLC021397

Date: 08th August, 2024

To,

The Head - Listing & Compliance

Metropolitan Stock Exchange of India Limited (MSEI)

Vibgyor Tower, 4th Floor,

Plot No. C-62, G - Block,

Opp. Trident Hotel

Bandra Kurla Complex

Mumbai-400098

ISIN - INE288U01011

Sub: Outcome of the Board Meeting held on 08th August, 2024

Dear Sir/Ma'am,

Pursuant to the Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Thursday, August 08, 2024, at 03:00 P.M. and concluded at 05:00 P.M. inter- alia, transacted and approved the following businesses:

1. Un-Audited Financial Results of the Company for the quarter ended June 30, 2024 along with Limited Review Report thereon.
2. Certificate of Non-Applicability of Regulation 32 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015
3. Approval of Board's Report along with related annexures for the financial year 2023-2024.
4. Took note of Secretarial Auditors Report and Certificate of Non disqualification of Directors for the Financial Year 2023-24 issued by Secretarial Auditor M/s Apoorv & Associates (C.P. No.: 21063).



BE SWASTH HEALTHCARE LIMITED

CIN: L93000DL1985PLC021397

5. Considered and approved the Date, Time, Venue and Notice of 38th Annual General Meeting of the Company which is scheduled to be held on Tuesday, September 10, 2024 at 1:00 P.M. at Maharaja Banquets, A-1/20A, Paschim Vihar, Main Rohtak Road, New Delhi 110063.

6. Decided Book Closure date i.e. from Tuesday, 3rd September, 2024 to Tuesday, 10th September, 2024 for the purpose of AGM and cut-off date for e-voting i.e. 3rd September, 2024.

7. Appointment of NSDL for conducting Remote E voting

8. Appointment of M/s Apoorv & Associates (C.P. No.: 21063) as Scrutinizer for conducting E-voting at AGM.

We request you to take the above on record.

Thanking you.

Yours Faithfully,

**For and on behalf of
Be Swasth Healthcare Limited**

**Amit Kumar
Company Secretary**



BE SWASTH HEALTHCARE LIMITED

CIN: L93000DL1985PLC021397

Date: 08th August, 2024

To,

The Head - Listing & Compliance

Metropolitan Stock Exchange of India Limited (MSEI)

Vibgyor Tower, 4th Floor,

Plot No. C-62, G - Block,

Opp. Trident Hotel

Bandra Kurla Complex

Mumbai-400098

ISIN - INE288U01011

SUB: Non-Applicability of Regulation 32 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015

Dear Sir/Ma'am,

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby confirms, that there has been no public issue proceeds raised from the Initial Public Issue (IPO), Further Public Issue (FPO), Right Issue, Preferential Issue, etc. during the reporting quarter ended on 30th June, 2024.

Hence, the statement of deviation(s) or variation(s) under Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the Company.

We request you to kindly take note of this information on your record and acknowledge.

Thanking You,

**For and on behalf of
Be Swasth Healthcare Limited**

**Amit Kumar
Company Secretary**



BE SWASTH HEALTHCARE LIMITED

CIN: L93000DL1985PLC021397

Date: 08th August, 2024

To,

The Head - Listing & Compliance

Metropolitan Stock Exchange of India Limited (MSEI)
Vibgyor Tower, 4th Floor,
Plot No. C-62, G - Block,
Opp. Trident Hotel
Bandra Kurla Complex
Mumbai-400098

ISIN - INE288U01011

Sub: SUBMISSION OF UN-AUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024 UNDER REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir/Ma'am,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) 2015, please find enclosed **Un-Audited Financial Results for the Quarter ended on June 30, 2024** along with Limited Review Report thereon approved by Board of Directors in their meeting held on August 08, 2024.

This is for your information and Records.

Thanking You,

**For and on behalf of
Be Swasth Healthcare Limited**

**Amit Kumar
Company Secretary**

P V R N & COMPANY

CHARTERED ACCOUNTANTS

6772/2, Block 10B, Sparda Bhawan , D.B Gupta Road, Dev Nagar,

Karol Bagh, New Delhi - 110005

Ph: - 01169115605

E - mail: pvrn_co@yahoo.co.in

Limited Review Report for the Quarter ended on June 30, 2024 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Be Swasth Healthcare Limited
812 Aggarwal Cyber Plaza-1,
Netaji Subhash Place,
Pitampura, Delhi-110034

We have reviewed the unaudited financial results of "**Be Swasth Healthcare Limited (the "Company")**" for the quarter ended June 30, 2024, which are included in the accompanying **'Statement of un-audited financial results for the quarter ended June 30, 2024'** together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PVR-N & Co.
Chartered Accountants
(FRN: 004062N)



Pradeep Kumar Jindal (Partner)

M. No. - 082646

UDIN :24082646BKAFBR8874

Place: New Delhi

Date: August 08, 2024

Be Swasth Healthcare Limited

CIN: L93000DL1985PLC021397

Regd. Office: 812, Aggarwal Cyber Plaza-1, Netaji Subhash Place, Pitampura, New Delhi-110034

Email Id: cs@be-swasth.com, Website: www.be-swasth.in, Ph: 011-46142960

Statement of Un-Audited Financial Results for the Quarter ended 30th June, 2024

Sr. No.	Particulars	Quarter Ended		(Amount in Lacs except EPS)	
		30-Jun-24	31-Mar-24	30-Jun-23	Year Ended
		Un-Audited	Audited	Un-Audited	31-Mar-24
I	Revenue from operations	2.25	6.16	2.25	29.98
II	Other Income	-	-	-	-
III	Total Income from operations (net) (I+II)	2.25	6.16	2.25	29.98
IV	Expenses				
	(a) Cost of raw materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expenses	0.90	5.09	2.37	16.91
	(e) Finance Cost	0.00	-	0.00	0.01
	(f) Depreciation and amortisation expense	0.08	0.11	0.11	0.43
	(g) Other expenses	1.58	1.17	0.82	5.55
	Total Expenses	2.56	6.37	3.30	22.89
V	Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)	(0.31)	(0.21)	(1.05)	7.09
VI	Exceptional Items				
VII	Profit/ (Loss) before extraordinary items and Tax (V-VI)	(0.31)	(0.21)	(1.05)	7.09
VIII	Extraordinary items				
IX	Profit/ (Loss) before Tax (VII-VIII)	(0.31)	(0.21)	(1.05)	7.09
X	Tax Expenses				
	Current Tax	-	-	-	1.78
	Deferred Tax	-	-	-	0.18
XI	Profit (Loss) for the period from continuing operations (IX-X)	(0.31)	(0.21)	(1.05)	5.12
XII	Net Profit/ (Loss) from discontinuing operation (before Tax)	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-
XIV	Net Profit/ (Loss) from discontinuing operation after Tax (XII-XIII)	-	-	-	-
XV	Net Profit/ (Loss) for the Period (XI+XIV)	(0.31)	(0.21)	(1.05)	5.12
XVI	Share of profit / (loss) of associates	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes,minority interest and share of profit/(loss) of associates	(0.31)	(0.21)	(1.05)	5.12
XIX	Other Comprehensive Income	-	-	-	-
XX	Total Comprehensive Income for the period (XVIII+XIX)	(0.31)	(0.21)	(1.05)	5.12
XXI	Paid-up equity share capital (Face value of Rs.10/- per share)	111.90	111.90	111.90	111.90
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				
XXIII	Earning Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)				
	A) Basic	(0.03)	(0.02)	(0.09)	0.46
	B) Diluted				

- 1 The Financial Results of the company has been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder.
- 2 The Statement of Un-Audited Financial results for the Quarter ended June 30, 2024 have been reviewed by the audit committee and approved by the Board of directors at their respective meeting held on 8th August, 2024. There are no qualifications in the Limited Review Report issued by the auditors.
- 3 There were no investor complaints pending during the quarter ended June 30, 2024
- 4 As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- 5 The Previous Quarter ended figures have been re-grouped/ re-arranged, whenever necessary.
- 6 There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.

Be Swasth Healthcare Limited

Place: New Delhi
Date: 8th August, 2024

Sushma Jain
Managing Director & CFO
DIN: 08545336